Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » Glucose Metabolism Disorders » Diabetes Mellitus » Diabetes Mellitus, Type 1
Diseases [C] » Endocrine System Diseases [C19] » Diabetes Mellitus » Diabetes Mellitus, Type 1
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Diabetes Mellitus, Type 1
Description
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. MeSH
Hierarchy View
Subtype Terms (1)
Wolfram Syndrome
3 approved drugs
Approved Indicated Drugs (4)
Phase 3 Indicated Drugs (36)
Phase 1 Indicated Drugs (68)
allogeneic adipose derived mesenchymal stem cell
autologous adipose-derived mesenchymal stem cells
autologous bone marrow derived mesenchymal cells
autologous human cord blood derived stem cells
bivalent oral polio vaccine (bopv), type 1 and type 3
Organization Involved with Phase 4 Indications (97)
Aristotle University of Thessaloniki
Buckinghamshire Healthcare NHS Trust
Canadian Institutes of Health Research (CIHR)
Gottfried Wilhelm Leibniz Universität Hannover
LMC Diabetes & Endocrinology Ltd.
Milton S. Hershey Medical Center
Mountain Diabetes and Endocrine Center
National Clinical Research Center for Metabolic Diseases, China
National Health and Medical Research Council, Australia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Sansum Diabetes Research Institute
State University of New York, Buffalo
Steno Diabetes Center Copenhagen
Technical University of Denmark
The University of Texas, Dallas
University Diabetes & Endocrine Consultants
University of Campania Luigi Vanvitelli
Organization Involved with Phase 3 Indications (112)
Almazov National Medical Research Centre
Assistance Publique - Hôpitaux de Paris
Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète
Gan and Lee Pharmaceuticals, USA
General Committee of Teaching Hospitals and Institutes, Egypt
Heart and Stroke Foundation of Canada
Hellenic Institute for the Study of Sepsis
Icahn School of Medicine at Mount Sinai
Integrated Medical Development
Jaeb Center for Health Research
Justus Liebig University Giessen
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
New Groote Schuur Hospital, Cape Town
NNF Center for Basal Metabolic Research, Denmark
Pediatric Clinic of AOU Novara
People's Liberation Army of China
Reproductive Endocrinology Associates of Charlotte
Samuel Lunenfeld Research Institute
Sanwa Kagaku Kenkyusho Co., Ltd.
Texas Diabetes & Endocrinology, P.A.
University of British Columbia
Organization Involved with Phase 2 Indications (142)
Alberta Innovates Health Solutions
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Boston Area Diabetes Endocrinology Research Center
Breath of Life International Pharma Ltd
California Institute for Regenerative Medicine (CIRM)
Children's Medical Center Dallas
City of Hope National Medical Center
Diabetes and Glandular Disease Research Associates Inc.
Diabetes Research Institute Foundation
Fondazione Italiana Diabete Onlus
German Center for Diabetes Research
German Federal Ministry of Education and Research
Health Resources and Services Administration (HRSA)
Helmholtz Centre for Infection Research
Institut fuer Diabetesforschung
Institut National de la Santé Et de la Recherche Médicale, France
Katholieke Universiteit Leuven
National Institute for Health Research, United Kingdom
Oregon Health and Science University
Ostergotland County Council, Sweden
Sir Jules Thorn Charitable Trust
Southern Star Research Pty Ltd.
Swedish Child Diabetes Foundation
Technical University of Dresden
Technical University of Munich
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Leona M. and Harry B. Helmsley Charitable Trust
The Research Council of South East Sweden
Translational Research Institute for Metabolism and Diabetes, Florida
University Health Network, Toronto
University of Alabama, Birmingham
University of California, Davis
University of California, Los Angeles
University of California, San Diego
University of Science Ho Chi Minh City
University of Texas at Houston
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (56)
Armed Police General Hospital, P. R. China
BioMimetix Pharmaceutical, Inc.
Children's Hospital Research Institute of Manitoba
Chinese Academy of Medical Sciences
High Point Clinical Trial Center
Manitoba Medical Service Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Nova Immunotherapeutics Limited
Organization Involved with Other Experimental Indications (52)
Abertawe Bro Morgannwg University
Association Rwandaise des Diabetiques
Case Western Reserve University
Central Hospital, Dijon, France
Central Hospital, Metz Thionville, France
Nemours Children's Health System
Postgraduate Institute of Medical Education and Research
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
